The FDA approved Roivant and Priovant’s brepocitinib for dermatomyositis, with the medicine marketed as Lisraya. It is the first major regulatory step for the oral drug and could expand Roivant’s autoimmune footprint. Dermatomyositis treatment has typically relied on high-dose steroids and other immune-suppressing therapies. Roivant said Lisraya is taken once daily, aiming to reduce the need for long-term steroid exposure. The approval also positions brepocitinib for broader payer and treatment-decision impact in a disease population with limited approved options.